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Abstract
One year after the beginning of the epidemic, mortality continues to be high 
despite several different protocols being tried. Critical patients with Covid 19 in 
some degree of organ failure and thrombotic events meet the diagnostic criteria of 
a complete or incomplete catastrophic antiphospholipid syndrome (CAPS) or at 
least we may need to consider a partial form of it. The findings of autopsies and the 
involvement of different organs and systems are similar to those of CAPS. Currently 
the only therapy that has been shown to reduce mortality include steroids, anti-
coagulation and an antinuclear antibody. The same therapy has been shown to be 
effective for CAPS.
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1. Introduction
After the COVID-19 outbreak in December 2019, a clinical picture was identi-
fied in most critical patients that was diagnosed as a cytokine storm associated with 
high mortality. Hypoxemia was also justified in those patients with severe ARDS 
who did not respond to the usual ventilation maneuvers such as a reflex of pul-
monary hypoxic vasoconstriction, which subsequently lost value or there were no 
more reports in this regard when thrombosis of pulmonary microvasculature was 
demonstrated.
After more than a year the medical community has been fighting COVID-19 and 
having published a number of articles perhaps like never before talking about the 
same subject in such a short time. We continue with almost the same mortality and 
with many unanswered questions about the fatal presentation with other systemic 
manifestations of the disease in patients who develop a serious clinical picture [1].
Obesity, hypertension, diabetes mellitus, cancer, and other chronic diseases have 
been clearly identified as risk factors for developing severe disease with complica-
tions. Just as after large studies it has been shown that the use of steroids, antico-
agulation and antinuclear antibodies considerably reduce mortality, being the only 
recommended treatment in critical patients. Antiviral treatment has been shown to 
help in ‘converting’ SAR-COV-2 virus positive patient into having a negative PCR 
result but has not been shown to modify mortality from the disease [2].
Severe and critical cases of COVID-19 generally present with multi-organ 
failure, evidence of thrombosis, marked elevation of ferritin, cytokine storm, some 
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patients with DIC but this is generally not a frequent event in the final stages of the 
disease.
Since March 2020, upon seeing this clinical presentation that appeared sud-
denly with high mortality, we began to raise the possibility initially in The Lancet 
rheumatologic, later in Expert Review of Respiratory Medicine about the possibility 
of taking into account the diagnosis of Catastrophic Antiphospholipid Antibody 
Syndrome (CAPS). However despite several studies having been carried out, espe-
cially relating to the presence or absence of antinuclear antibodies in patients with 
COVID-19, we have not found any that has made this diagnosis even after meeting 
the criteria, much less has it been treated as such. However, drugs have been used 
in COVID-19 that have been shown to reduce mortality in that are part of the CAPS 
therapeutic arsenal, even in children with multisystemic inflammatory syndrome, 
immunoglobulins have been used with good results [3].
The presence of antiphospholipid antibodies have been reported in patients 
with COVID-19 with a percentage that ranges from 9–96% depending on sever-
ity of condition and the presence of thrombosis. Overall figures are around 54%, 
however, in few studies its presence is associated with failure of more than three 
organs, thrombosis, and even elevated ferritin which meets the criteria for making a 
diagnosis of CAPS [4].
Catastrophic Antiphospholipid Antibody Syndrome or Asherson’s syndrome to 
honor Ronald A. Asherson for his impressive work on this condition was named in 
1992 when catastrophic was added to define an accelerated form of the antiphos-
pholipid syndrome (APS). CAPS is a rare phenomenon, according to the CAPS 
registry, it occurs in around 1% of all antiphospholipid syndromes, however, since 
it is a little-studied entity and at the same time little known by doctors, we infer 
that it is underdiagnosed [5].
2. Precipitating factors in CAPS
Infections
Postpartum or recent fetal loss
Minor surgical procedures or surgery
Other: malignancy, medication, anticoagulation withdrawal, and SLE 
exacerbation.
Although the pathogenesis of CAPS continues to be insufficiently understood, 
antiphospholipid (aPL) antibodies (Ab) belong to the immunoglobulin (Ig) family 
and are directed against phospholipid-binding plasma proteins such as Beta2 
Glycoprotein1 (B2- GP1), prothrombin, annexin V, PS, PC, etc.
As a consequence of initial damage, anionic phospholipids would be exposed on 
the cell surface B2-GP1. If there are circulating anti-B2-GP1 Ab, they will bind to 
this complex, inducing cell activation with the release of tissue factor (TF), adhe-
sion molecules, IL-8, C3b, C5a, among others, such as the activation of leukocytes 
and platelets. This increases their adhesion to the vascular endothelium, promoting 
microthrombosis and promoting the release of proteases and free radicals. Multiple 
vascular occlusion triggers necrosis tissue with excessive release of cytokines. A 
present marker is ferritin, which is elevated in 71% of CAPS patients and according 
to a recent study could play a role in the pathogenesis of APS and as a follow-up 
marker in CAPS [6, 7].
Kitchen postulates that vascular occlusion triggers additional thrombosis 
(“thrombotic storm”), which leads to increased thrombin and decreased fibri-
nolysis. As her son proposes the theory of “molecular mimic-cry” (molecular 
imitation), where on one hand the anti-B2-GP1 Ab when bound to the B2-GP1 of 
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the endothelial cell generate a procoagulant state and on the other hand, certain 
viruses and bacteria that have an amino acid sequence similar to that of B2-GP1. 
This therefore favors the synthesis of more Ab. Furthermore, B2-GP1 could activate 
the immune response through interaction with a membrane receptor TLRs (toll-
like) and from this a series of signals are generated, which increase the production 
of proinflammatory cytokines (TNF, IL-1B, IL-6, IL.8) and FT, PAI-1, PAF, etc. 
leading to multi-organ failure [8].
3.  The criteria for the classification of catastrophic antiphospholipid 
antibody syndrome
1. Evidence of involvement of three or more organs, systems, or tissues.
2. Development of manifestations simultaneously or in less than a week.
3. Confirmation by histopathology of small-vessel occlusion in at least one organ 
or tissue.
4. Laboratory confirmation of the presence of antiphospholipid antibodies 
( lupus anticoagulant or anticardiolipin antibodies) [5].
4. Probable catastrophic antiphospholipid antibody syndrome
1. All four criteria, except only two organs, systems, or tissues are involved
2. All four criteria, except for the absence of laboratory confirmation at least 
6 weeks apart because of the early death of a patient never previously tested 
for aPL before the catastrophic event.
3. Criteria 1, 2, and 4
4. Criteria 1, 3, and 4, and the development of a third event in more than a week, 
but less than a month, despite anticoagulation.
There are several reports during this pandemic where a high incidence of 
antiphospholipid antibodies has been demonstrated in patients with COVID-19. 
In addition, multiorgan failure and the presence of microthrombosis in critical 
patients have been associated with cytokine storm and the elevated ferritin. From 
the first reports in Wuhan, elevated ferritin was identified as a marker of severity 
in critically ill patients with COVID-19. Four well-recognized clinical conditions 
may be associated with high ferritin levels: the macrophage activation syndrome 
(MAS), adult-onset Still’s disease (AOSD), catastrophic antiphospholipid syndrome 
(CAPS), and septic shock. The presentation of critical patients with COVID-19 does 
not meet the criteria to make a diagnosis of any of these diseases, however, they do 
meet the criteria to make the diagnosis of complete or incomplete CAPS [9, 10].
However a study by the American society of Hematology (ASH) in which they 
performed an antiphospholipid antibody (aPL) screen in 27 patients with COVID-
19. Only four of these patients were positive for lupus anticoagulant. None of these 
patients were positive for anticardiolipin or anti-β-2 glycoprotein I antibodies. 
Given the fact that antiphosholipid antibodies may transiently be elevated during 
acute infections, thrombosis or inflammation, the American Society of Hematology 
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has strongly recommended against routinely testing for these antibodies (aPL) in 
COVID-19 patients unless clinically indicated by the history.
It is however important to note that most studies that have been published in this 
regard do not report findings specific for critical patients with COVID-19. Inclusion 
criteria have been more generalized targeting patients with COVID-19. This could 
lead to recording lower positivity rate for aPL antibodies. Also, most of these stud-
ies have only tested specifically for lupus anticoagulant which is the least sensitive 
among the different types of antiphospholipid antibodies which could be positive 
among this group [11].
This recently led Amezcua-Guerra et al. to test a panel of aPL antibodies in 
blood specimens from 21 patients hospitalized in the intensive care unit due to 
severe or critical COVID-19. Anticardiolipin, anti-β2 glycoprotein I, antiprothrom-
bin, antiphosphatidylserine, antiphosphatidylinositol and antiannexin V antibodies 
were measured, each in IgM and IgG isotypes. Subsequently, demographic and clin-
ical data were obtained from electronic medical records. Samples (sera) collected 
before the SARS-CoV-2 pandemic from 12 healthy individuals, matched for age and 
sex, were tested as controls. A total of 19 patients (90%) had dyspneoa while on 
admission, 57% eventually required mechanical ventilation (invasive) during their 
stay in the hospital. All of these patients had elevated levels of D-dimer, ferritin and 
C reactive protein at time of presentation.
Out of the 21 patients with COVID-19, 12 of them tested positive for at least one 
aPL antibody with only 1 of the 12 controls yielding a positive result. Age and num-
ber of comorbidities tended to be lower in patients with aPL antibodies. In contrast, 
levels of D-dimer, ferritin and C reactive protein were higher both on admission 
and throughout the hospital stay in the patients. Patients who were positive for aPL 
demonstrated elevated levels of interleukin-6 (>40 pg./mL) [12].
Interestingly, significant levels of circulating anticardiolipin and anti-β-
2glycoprotien I antibodies have recently been described in three severely ill COVID-
19 patients with multiple cerebral infarctions by Zhang et al. This is suggestive that 
coagulopathy associated with COVID-19 could be within or close to the spectrum 
of antiphospholipid syndrome. A higher-than-expected number of thrombotic 
episodes have been reported involving both veins and arteries (pulmonary throm-
boembolism, deep venous thromboses, myocardial infarction and stroke even with 
the use of anticoagulant therapy or prophylaxis [13].
It is now established that vascular changes are well associated with COVID-19. 
Formation of fibrin thrombi has been observed in some patients. Many patients 
with severe illness have shown elevated levels of D-Dimers with other clinically 
relevant findings suggesting thrombotic microangiopathy such as cutaneous 
changes in the limbs. Autopsy finding of four out of seven patients with COVID-
19 showed that thrombi were consistently present in all pulmonary vessels with 
a diameter of 1 mm- 2 mm. Also, microthrombi were 9 times more likely to be 
found in the alveolar capillaries of patients with COVID-19 than in patients with 
influenza [14].
5. Clinical manifestations of CAPS
Renal (70%): usually accompanied by hypertension and acute renal failure.
Pulmonary (65%): severe dyspnea, frank adult respiratory distress syndrome 
(ARDS), pulmonary emboli, sometimes multiple pulmonary infarction, interstitial 
infiltrates, and intraalveolar hemorrhage.
Central nervous system (55%): major cerebral infarctions, cerebral sinus throm-
bosis, encephalopathy and seizures.
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Cardiac (50%): typical myocardial infarction, diffuse myocardial involvement 
with congestive heart failure or valve lesions.
Gastrointestinal (45%): vascular occlusions of mesenteric, portal and inferior 
vena cava, arterial occlusions accompanied by gangrene of the bowels and splenic 
infarctions, hepatic involvement and pancreatitis.
Skin (40–45%): livedo reticularis, ulcerations, gangrene, purpura, acrocyanosis 
or digital ischemia.
Other manifestations: adrenal thrombosis, testicular infarction, necrosis of the 
prostate gland [7].
The clinical manifestations are described in multiple reports during the coronavi-
rus pandemic including skin involvement, so we believe, according to the evidence, 
that a high percentage of critically ill patients meet the diagnostic criteria of this entity.
Coagulation disorders were initially thought to be due to diseminated intravas-
cular coagulopathy (DIC), but with the current evidence from all autopsies it has 
been shown to be due to a procoagulant phenomenon together with a severe inflam-
matory state. These findings may explain the events of venous thromboembolism 
observed in some of these patients and support antithrombotic prophylaxis/treat-
ment. The cumulative incidence of thrombotic complications (mostly PE) is high 
between 25 and 30%.
The incidence of cerebral thrombosis in two weeks is almost 10 times higher in 
patients with COVID-19 than in the normal population in patients under 50 years of 
age. In a report of 3 patients with ischemic stroke the association with antiphosphil-
ipid antibodies was 100% [15, 16].
This multisystem inflammatory syndrome is caused by cytokine activation [7]. 
Cytokines involved include tumor necrosis factor (TNF)-α, interleukin (IL)-1, IL-6, 
IL-18 and macrophage-migration inhibitory factor. These cytokines are responsible 
for acute lung inflammation via increasing neutrophil migration and lung vascular 
permeability, not only for ARDS but also for the cerebral edema, which may be a 
factor in the initial confusion and deterioration of consciousness in these patients, 
as well as myocardial dysfunction encountered.
In 6 autopsies performed in a hospital in France it was found that one patient 
presented a lymphocytic viral pneumonia that could be considered as type L. For 
five other patients with a phenotype H, the histologic pattern was an acute fibrinous 
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and organizing pneumonia (AFOP), characterized by an extensive intra-alveolar 
fibrin deposition called fibrin “balls”, rather than hyaline membranes. AFOP, a rare 
form of acute lung injury. This pattern differs from the diffuse alveolar damage 
(DAD) found in the classic ARDS by the fact that organizing intra alveolar fibrin 
constitutes the dominant histological finding in AFOP, especially in its subacute 
presentation by contrast to the fulminant presentation, is a cortico-sensitive 
pathology.
Kidney histopathology was examined in an autopsy series of 26 patients who 
died of respiratory failure secondary to COVID-19. All patients had evidence of 
acute tubular injury (of varying severity); a range of other histopathology findings, 
such as erythrocyte clusters and pigmented casts, were also present [17].
Myocardial involvement has been described since the first reports adding an 
increase in the incidence of ACS and arrhythmias in these patients. Reports vary 
20–30% of myocardial involvement, even higher percentages of troponin elevation 
have been found as a marker of myocardial damage [18].
The slightly rarer skin manifestations in this entity, especially when it is second-
ary to an infectious process, have been reported in two articles, even during the 
autopsy of these patients with purpuric skin rash. The conclusions of this study 
were severe COVID-19 may define a type of catastrophic microvascular injury 
syndrome mediated by activation of complement pathways and an associated 
procoagulant state.
In the CAPS Registry, CAPS as the initial manifestation of antiphospholipid 
syndrome occurred in 86.6% of children with infections being the triggering factor 
in 60.9% of the cases. Cardiac involvement was present in 57.4% of children and 
included cardiac failure, heart valve lesions, lung 63%, skin 37% and gastrointesti-
nal 17.4% [19, 20].
Infections in children are more frequent than adults, which have been shown to 
play a role in the theory of “molecular mimic-cry” (molecular imitation) where cer-
tain viruses and bacteria that have an amino acid sequence similar to that of B2-GP1 
result in an immune response producing antiphospholipid antibodies. B2-GP1 could 
activate the immune response through interaction with a membrane receptor TLRs 
(toll-like) and from this a series of signals are generated, which increase the produc-
tion of proinflammatory cytokines. The medical community recognizes the MIS but 
most do not agree with the diagnosis of kawassaki disease [16].
Given the data made available from the various studies mentioned earlier, we 
can say that there is some evidence that critically ill patients with COVID-19 are 
demonstrating a disease form that meets the criteria for making the diagnosis of 
complete catastrophic antiphospholipid antibodies syndrome, or at least show-
ing a disease form that is within the spectrum of manifestation of this syndrome. 
CAPS registry was created in 2000. As of 2012 it had been updated with data from 
over 400 patients. Not much advancement has been made in the area of this poorly 
understood syndrome after that. This interesting phenomenon observed during this 
pandemic which has become the largest public health emergency in recent times 
calls for more research work in the area of Catastrophic antiphospholipid syn-
drome. More awareness is required in the medical community in this area [21–23].
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